1.Experimental study on the effect of Ginsenoside Rg1 on the pathological changes of rat optic nerve injury
Bo HUANG ; Fangwei YING ; Qiaoyan LONG ; Wenxue HU
Chinese Journal of Primary Medicine and Pharmacy 2011;18(18):2453-2454
ObjectiveTo study the effect of ginsenoside Rg1 on the pathological changes of rat optic nerve injury. MethodsThe model of rat optic nerve injury was established, the rats were divided into the experimental group and control group,intraperitonealiy injected ginsenosides Rgl (10mg/kg) to experimental group of rats for 20days ,meanwhile intraperitonealiy injected the same volume of saline to the control group,took eyeball and optic nerve from the optic nerve injury eye and the normal eye in both groups ,HE staining,SABC immunohistochemical staining of Bcl-2, neurocan were analyzed. ResultsHE staining results showed the morphological difference on optic nerve cells from control group and the optic nerve injury group. Immunohistochemistry showed the neuronal cell apoptosis was significantly increased after optic nerve injury. The intraperitoneal injection of ginsenoside Rg1 could significantly improve the situation of cell apoptosis. The significant increment of fiber protein may be partly related to the improvement of cell apoptosis, but the principle was not clear. ConclusionGinsenoside Rg1 had protective effect on rat optic nerve injury.
2.Improving maltodextrin specificity by site-saturation engineering of subsite +1 in cyclodextrin glycosyltransferase from Paenibacillus macerans.
Qiaoyan XU ; Ruizhi HAN ; Jianghua LI ; Guocheng DU ; Long LIU ; Jian CHEN
Chinese Journal of Biotechnology 2014;30(1):98-108
By engineering the subsite +1 of cyclodextrin glycosyltransferase (CGTase) from Paenibacillus macerans, we improved its maltodextrin specificity for 2-O-D-glucopyranosyl-L-ascorbic acid (AA-2G) synthesis. Specifically, we conducted site-saturation mutagenesis on Leu194, Ala230, and His233 in subsite +1 separately and gained 3 mutants L194N (leucine --> asparagine), A230D (alanine --> aspartic acid), and H233E (histidine --> glutamic acid) produced higher AA-2G yield than the wild-type and the other mutant CGTases. Therefore, the 3 mutants L194N, A230D, and H233E were further used to construct the double and triple mutations. Among the 7 obtained combinational mutants, the triple mutant L194N/A230D/H233E produced the highest AA-2G titer of 1.95 g/L, which was increased by 62.5% compared with that produced by the wild-type CGTase. Then, we modeled the reaction kinetics of all the mutants and found a substrate inhibition by high titer of L-AA for the mutants. The optimal temperature, pH, and reaction time of all the mutants were also determined. The structure modeling indicated that the enhanced maltodextrin specificity may be related with the changes of hydrogen bonding interactions between the side chain of residue at the three positions (194, 230 and 233) and the substrate sugars.
Ascorbic Acid
;
analogs & derivatives
;
chemistry
;
Glucosyltransferases
;
genetics
;
metabolism
;
Hydrogen Bonding
;
Kinetics
;
Mutagenesis, Site-Directed
;
Paenibacillus
;
enzymology
;
Polysaccharides
;
chemistry
;
Protein Engineering
;
Substrate Specificity
;
Temperature
3.Generation of a Hutchinson-Gilford progeria syndrome monkey model by base editing.
Fang WANG ; Weiqi ZHANG ; Qiaoyan YANG ; Yu KANG ; Yanling FAN ; Jingkuan WEI ; Zunpeng LIU ; Shaoxing DAI ; Hao LI ; Zifan LI ; Lizhu XU ; Chu CHU ; Jing QU ; Chenyang SI ; Weizhi JI ; Guang-Hui LIU ; Chengzu LONG ; Yuyu NIU
Protein & Cell 2020;11(11):809-824
Many human genetic diseases, including Hutchinson-Gilford progeria syndrome (HGPS), are caused by single point mutations. HGPS is a rare disorder that causes premature aging and is usually caused by a de novo point mutation in the LMNA gene. Base editors (BEs) composed of a cytidine deaminase fused to CRISPR/Cas9 nickase are highly efficient at inducing C to T base conversions in a programmable manner and can be used to generate animal disease models with single amino-acid substitutions. Here, we generated the first HGPS monkey model by delivering a BE mRNA and guide RNA (gRNA) targeting the LMNA gene via microinjection into monkey zygotes. Five out of six newborn monkeys carried the mutation specifically at the target site. HGPS monkeys expressed the toxic form of lamin A, progerin, and recapitulated the typical HGPS phenotypes including growth retardation, bone alterations, and vascular abnormalities. Thus, this monkey model genetically and clinically mimics HGPS in humans, demonstrating that the BE system can efficiently and accurately generate patient-specific disease models in non-human primates.
Animals
;
Disease Models, Animal
;
Female
;
Gene Editing
;
Humans
;
Lamin Type A/metabolism*
;
Macaca fascicularis
;
Progeria/pathology*